A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Recurrent/Metastatic Breast Cancer
Interventions: DRUG: Inetetamab, pyrotinib, chemotherapy
Sponsor: Fujian Medical University